Products for Research Use Only
RegisterLogin

INX-315

CAT: 0804-HY-162001-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-162001-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
INX-315 is an orally active and selective CDK2 inhibitor that induces cell cycle arrest in the G1 phase. INX-315 reduces CDK2 substrate phosphorylation and inhibits tumor growth in a dose-dependent manner in xenograft mouse models. INX-315 may be used in cancer research[1].
CAS Number
2745060-92-6
UNSPSC
12352005
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/inx-315.html
Purity
99.75
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(NN1)C2(CCCCC2)N(C1=C3)C4=C3C=NC(NC5=CC=C(S(=O)(N)=O)C=C5)=N4
Molecular Formula
C19H21N7O3S
Molecular Weight
427.48
References & Citations
[1]Dietrich C, et al. INX-315, a selective CDK2 inhibitor, induces cell cycle arrest and senescence in solid tumors. Cancer Discov. 2023 Dec 4. |[2]Trub A G, et al. INX-315, a potent and selective CDK2 inhibitor, demonstrates robust antitumor activity in CCNE1-amplified cancers[J]. Cancer Research, 2023, 83 (7_Supplement) : 5994-5994.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Related Products

CatalogName
HY-160182-01INX-P
HY-160181-01INX-SM-3
HY-147119-01INX-SM-6
HY-147179-01INX-SM-56
HY-14334SAM-315
HY-178723AMG-315
HY-19894LTX-315
HY-117608-01ML 315
HY-117608A-01ML 315 (hydrochloride)
HY-W953136CRBN ligand-315

Alternative Products

CatalogName
BA3766-5.1INX-315
A24277-50INX-315 50mg
A24277-100INX-315 100mg
A24277-10INX-315 10mg
A24277-5INX-315 5mg
MBS3600937-01INX-08189
529117INX 08189
GTR19234320-01INX-P
BA2355-1INX-SM-56
T77851-01INX-SM-6

Popular Products